These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. GDNF increases cell motility in human colon cancer through VEGF-VEGFR1 interaction. Huang SM; Chen TS; Chiu CM; Chang LK; Liao KF; Tan HM; Yeh WL; Chang GR; Wang MY; Lu DY Endocr Relat Cancer; 2014 Feb; 21(1):73-84. PubMed ID: 24165321 [TBL] [Abstract][Full Text] [Related]
25. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Hong TM; Chen YL; Wu YY; Yuan A; Chao YC; Chung YC; Wu MH; Yang SC; Pan SH; Shih JY; Chan WK; Yang PC Clin Cancer Res; 2007 Aug; 13(16):4759-68. PubMed ID: 17699853 [TBL] [Abstract][Full Text] [Related]
26. Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076). Ko JH; Kwon HS; Kim B; Min G; Shin C; Yang SW; Lee SW; Lee Y; Hong D; Kim YS Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32560565 [TBL] [Abstract][Full Text] [Related]
27. Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization. Cakmak H; Gokmen E; Bozkurt G; Kocaturk T; Ergin K Cutan Ocul Toxicol; 2018 Jun; 37(2):191-195. PubMed ID: 28874077 [TBL] [Abstract][Full Text] [Related]
28. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461 [TBL] [Abstract][Full Text] [Related]
29. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162 [TBL] [Abstract][Full Text] [Related]
30. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888 [TBL] [Abstract][Full Text] [Related]
31. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Damiano V; Caputo R; Garofalo S; Bianco R; Rosa R; Merola G; Gelardi T; Racioppi L; Fontanini G; De Placido S; Kandimalla ER; Agrawal S; Ciardiello F; Tortora G Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12468-73. PubMed ID: 17636117 [TBL] [Abstract][Full Text] [Related]
32. Placental NRP1 and VEGF expression in pre-eclamptic women and in a homocysteine-treated mouse model of pre-eclampsia. Xu X; Yang XY; He BW; Yang WJ; Cheng WW Eur J Obstet Gynecol Reprod Biol; 2016 Jan; 196():69-75. PubMed ID: 26708340 [TBL] [Abstract][Full Text] [Related]
33. Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Kiso M; Tanaka S; Saji S; Toi M; Sato F Int J Cancer; 2018 Dec; 143(11):2905-2918. PubMed ID: 29971782 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. Gray MJ; Van Buren G; Dallas NA; Xia L; Wang X; Yang AD; Somcio RJ; Lin YG; Lim S; Fan F; Mangala LS; Arumugam T; Logsdon CD; Lopez-Berestein G; Sood AK; Ellis LM J Natl Cancer Inst; 2008 Jan; 100(2):109-20. PubMed ID: 18182619 [TBL] [Abstract][Full Text] [Related]
35. Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis. Kim YJ; Bae J; Shin TH; Kang SH; Jeong M; Han Y; Park JH; Kim SK; Kim YS J Control Release; 2015 Oct; 216():56-68. PubMed ID: 26260451 [TBL] [Abstract][Full Text] [Related]
36. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis. Zhou R; Curry JM; Roy LD; Grover P; Haider J; Moore LJ; Wu ST; Kamesh A; Yazdanifar M; Ahrens WA; Leung T; Mukherjee P Oncogene; 2016 Oct; 35(43):5608-5618. PubMed ID: 26804176 [TBL] [Abstract][Full Text] [Related]
37. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model. Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037 [TBL] [Abstract][Full Text] [Related]
38. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848 [TBL] [Abstract][Full Text] [Related]
39. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Shojaei F; Lee JH; Simmons BH; Wong A; Esparza CO; Plumlee PA; Feng J; Stewart AE; Hu-Lowe DD; Christensen JG Cancer Res; 2010 Dec; 70(24):10090-100. PubMed ID: 20952508 [TBL] [Abstract][Full Text] [Related]
40. Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials. Li Y; Huang X; Zhang Q; Ma K Mol Med Rep; 2013 Aug; 8(2):655-61. PubMed ID: 23778885 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]